Skip to main content

Mydayis FDA Approval History

Last updated by Judith Stewart, BPharm on April 9, 2021.

FDA Approved: Yes (First approved June 20, 2017)
Brand name: Mydayis
Generic name: amphetamine mixed salts
Company: Shire plc
Treatment for: Attention Deficit Hyperactivity Disorder (ADHD)

Add Drugs.com as a trusted source

Add Drugs.com as a trusted source on Google to see more of our health news and information in your Google Search results.

  1. Tap the button to open Google's source settings.
  2. Tick the box next to Drugs.com.
  3. You can change it anytime in your Google settings.

Requires a signed-in Google account.

Mydayis (amphetamine mixed salts) is a central nervous system (CNS) stimulant indicated for the treatment of Attention Deficit Hyperactivity Disorder (ADHD) in patients 13 years and older.

Development timeline for Mydayis

DateArticle
Jun 21, 2017Approval FDA Approves Mydayis (mixed salts of a single-entity amphetamine product) – A New Once-Daily Option for ADHD
May 21, 2007FDA Issues Approvable Letter for SPD465 (Triple-Bead MixedAmphetamine Salts) for the Treatment of ADHD in Adults
Jul 21, 2006Shire Announces Filing of SPD465 for the Treatment of Adult ADHD

See also

Mydayis (amphetamine mixed salts) Consumer information

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Medical Disclaimer